The invention relates to a method for the treatment or prevention of a condition or disease selected from the group consisting of hypertension, (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, myocardial infarction and its sequelae, supraventricular and ventricular arrhythmias, atrial fibrillation or atrial flutter, atherosclerosis, angina (whether stable or ustable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, hypertension in patients with NIDDM, secondary aldosteronism, primary and secondary pulmonary hyperaldosteronism, primary and pulmonary hypertension, renal failure conditions, such as diabetic nephropathy,glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), and stroke, comprising administering a therapeutically effective amount of combination of (i) the AT 1 -antagonists valsartan or a pharmaceutically acceptable salt thereof and (ii) a Calcium channel blocker or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier to a mammal in need of such treatment and to corresponding pharmaceutical combination composition.Oppfinnelsen vedrører en fremgangsmåte for behandlingen eller forebyggelsen av en tilstand eller sykdom valgt fra gruppen bestående av hypertensjon, (akutt og kronisk) kongestiv hjertesvikt, venstre ventrikkeldysfunksjon og hypertropisk kardiomyopati, myokardialt infarkt og dets følgetilstander, supraventrikkel og ventrikkelarrytmier, atrerieflimmer eller atrerieflutter, aterosklerose, angia (enten stabil eller ustabil), nyresvikt (diabetes og ikke-diabetes), hjertesvikt, angina pectoris, diabetes, hypertensjon hos pasienter med NIDDM, sekundær aldosteronisme, primær og seku
